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Role of Carbonate in the Cytotoxicity of Carboplatin
Anthony J. Di Pasqua,† Jerry Goodisman,† Deborah J. Kerwood,† Bonnie B. Toms,‡
Ronald L. Dubowy,‡ and James C. Dabrowiak*,†
Department of Chemistry, Syracuse UniVersity, 111 College Place, CST, Room 1-014, Syracuse, New York
13244-4100, and Department of Pediatrics, Upstate Medical UniVersity, State UniVersity of New York,
750 East Adams Street, Syracuse, New York 13210
ReceiVed February 15, 2007

Carboplatin, [Pt(NH3)2(CBDCA-O,O′)], 1, where CBDCA is cyclobutane-1,1-dicarboxylate, is used
against ovarian, lung, and other types of cancer. We recently showed (Di Pasqua et al. (2006) Chem.
Res. Toxicol. 19, 139-149) that carboplatin reacts with carbonate under conditions that simulate therapy
to produce carbonato carboplatin, cis-[Pt(NH3)2(O-CBDCA)(CO3)]2-, 2. We use 13C and 1H NMR and
UV-visible absorption spectroscopy to show that solutions containing carboplatin that have been aged
in carbonate buffer under various conditions contain 1, 2, and other compounds. We then show that
aging carboplatin in carbonate produces compounds that are more toxic to human neuroblastoma (SKN-SH), proximal renal tubule (HK-2) and Namalwa-luc Burkitt’s lymphoma (BL) cells than carboplatin
alone. Moreover, increasing the aging time increases the cytotoxicity of the platinum solutions as measured
by the increase in cell death. Although HK-2 cells experience a large loss in survival upon exposure to
carbonato forms of the drug, they have the highest values of IC50 of the three cell lines studied, so that
HK-2 cells remain the most resistant to the toxic effects of the carbonato forms in the culture medium.
This is consistent with the well-known low renal toxicity observed for carboplatin in therapy. The uptake
rates for normal Jurkat cells (NJ) and cisplatin-resistant Jurkat cells (RJ), measured by inductively coupled
plasma mass spectrometry (ICP-MS), are 16.6 ( 4.2 and 12.3 ( 4.8 amol of Pt h-1 cell-1, respectively,
when exposed to carboplatin alone. However, when these cells are exposed to carboplatin that has been
aged in carbonate media, normal Jurkat cells strongly bind/take up Pt at a rate of 14.5 ( 4.1 amol of Pt
h-1 cell-1, while resistant cells strongly bind/take up 5.1 ( 3.3 amol of Pt h-1 cell-1. Collectively, these
studies show that carboplatin carbonato species may play a major role in the cytotoxicity and uptake of
carboplatin by cells.
Introduction
Platinum drugs by themselves or in combination with other
agents are used to treat many types of human cancer (1-5).
These remarkable compounds are believed to exert their
biological effects by interacting with genomic DNA, but other
cellular targets may be attacked as well (6). Although research
on the platinum drugs spans nearly four decades (7, 8), the forms
of the agents that circulate in the blood, the mechanism by which
they enter the cell, and the main events that lead to drug-induced
cell death are not known with certainty.
Carboplatin,1 [Pt(NH3)2(CBDCA-O,O′)], where CBDCA is
cyclobutane-1,1-dicarboxylate, 1, Scheme 1, is a secondgeneration Pt2+ anti-cancer drug, which is in wide clinical use
for the treatment of ovarian, lung, and other types of cancer
(1). Carboplatin contains a bidentate dicarboxylate chelate as a
leaving ligand, which makes the drug much less reactive than
its close analogue cisplatin, cis-Pt(NH3)2Cl2, which contains two
monodentate chlorides as leaving ligands. The reduced reactivity
* To whom correspondence should be addressed: tel 315-443-4601; fax
315-443-4070; e-mail jcdabrow@syr.edu.
† Syracuse University.
‡ State University of New York.
1 Abbreviations: carboplatin, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II), Pt(NH3)2(CBDCA-O,O′); CBDCA, cyclobutane-1,1-dicarboxylate; cisplatin, cis-diamminedichloroplatinum(II); D2O, deuterium
oxide; FBS, fetal bovine serum; PBS, phosphate-buffered saline; amol,
attomole or 10-18 mol; aC, activity of CO32-; γC, activity coefficient of
CO32-.

of 1 compared to cisplatin can easily be seen in the different
hydrolysis rates of the two compounds. At neutral pH at 37 °C,
the rate constant for the reaction of 1 with water, which involves
displacement of one arm of the CBDCA chelate ring, is k ≈ 5
× 10-7 s-1, although smaller values of the hydrolysis rate
constant have also been reported (9-12). By comparison, the
rate constant for displacement of one of the chloro ligands of
cisplatin with water at 35.5 °C is 1.8 × 10-4 s-1 (13), which is
more than 2 orders of magnitude larger than for 1. While it is
easy to see that the substitution kinetics of cisplatin are fast
enough to allow the drug to react with water and biological
components under the conditions of therapy, the slower
substitution kinetics of carboplatin have prompted investigators
to focus on mechanisms by which the compound can be
activated in vivo. Activation would involve the complete or
partial displacement of the CBDCA ligand of 1 to give a product
that is competent to react with DNA and other biological targets.
Since sulfur in a thiolate or thioether is considered a soft
base and Pt2+ is a soft acid (14), investigations have focused
on the ability of cysteine and methionine, or peptides and
proteins containing these amino acids, to react with carboplatin
(15-20). As expected, these nucleophiles displace the CBDCA
ligand at rates that are much larger than that for water to give
a variety of different products. For example reaction of 1 with
methionine proceeds with a second-order rate constant of k )
2.7 × 10-3 M-1 s-1 to initially give a ring-opened product
having a monodentate CBDCA ligand and S-bonded methionine.
This product is surprisingly stable to methionine chelate ring
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Scheme 1. Reaction of Carboplatin in Carbonate Buffer

closure and loss of CBDCA (15). Most studies have shown that
the rate of reaction of carboplatin with nucleotides and purified
polymeric DNA is slow, strongly suggesting that some form of
activation is necessary if DNA platination is to occur under
conditions of therapy (21, 22). However, in the presence of
sulfur-containing nucleophiles, the rate of binding of carboplatin
to DNA is enhanced and the nature of the products formed is
different than in the absence of these nucleophiles (21, 22). A
recent study by Henderson and co-workers (23) applied accelerator mass spectrometry to show that the rate of reaction of
carboplatin with purified polymeric DNA is faster than the rate
of reaction of the drug with dGMP (12), suggesting that that
the drug may not require activation for facile reaction with DNA.
Culture media, blood, and the cytosol contain high concentrations of carbonate, which, because it is a good ligand for
transition metal ions (24, 25), may play an important role in
the mechanism of action of carboplatin and other platinum drugs.
Carbonate at pH 7.4 is mostly in the form of bicarbonate,
HCO3-, but this form is in equilibrium with carbonate (CO32-),
carbonic acid (H2CO3), and dissolved CO2. Extensive work
has shown that carbonato complexes can form by the rapid addition of carbon dioxide to a metal hydroxo species or by a
slower route involving ligand displacement by carbonate or
bicarbonate (24).
Carbonato complexes, which were first reported by Werner
and Goslings in 1903 (26), are known for a large number of
metal ions (24, 25, 27) including Pt2+. Complexes of the latter
can be mononuclear with bidentate carbonate (28-34) or
dinuclear with bridging carbonate (35) usually with phosphine
ligands (28-32, 35). However, 1,2-diaminocyclohexane (DACH)
(33, 34), the nonleaving ligand in the drug oxaliplatin (3), has
also been incorporated into platinum carbonato complexes.
These compounds can be made by metathesis reactions involving a cis-dichloro complex and silver carbonate (30, 33, 34),
addition of carbon dioxide to hydrido (28), hydroxo (29, 35),
or dioxygen (32) species, or hydrolysis of N,N-diethylcarbamato
compounds.31 An unusual cyclo-tetranuclear complex of Pt2+
having bridging carbonates and cis-ammonia molecules has also
been reported to form as a minor product in the reaction of
cisplatin with 2′-deoxyuridine (36). Although the mechanism
by which the tetranuclear complex is formed is not known,
atmospheric CO2 is probably involved in the process (29). While
square planar complexes of Pd2+ having bound water readily
form carbonato complexes in aqueous carbonate solutions (37)

the corresponding complexes of Pt+2 have been reported to be
unreactive under the same conditions (38).
Ready-to-use carboplatin infusion solutions have a typical
shelf life of ∼14 months during which time, depending on the
storage temperature, a few percent is hydrolyzed to the ringopened complex (39). Since blood contains ∼24 mM carbonate,
2.1 mM of which is aquated CO2 at pH 7.4 (24), infusion of
the drug solution into blood could result in the rapid formation
of small amounts of monocarbonato species by reaction of a
carboplatin aquo/hydroxo compound with dissolved CO2. By
comparison the ready-to-use cisplatin infusion solution, for
example, Platinol, contains ∼5% aquated forms, mostly as the
monoaquo complex (13). As was earlier shown by us (9),
carbonate ion (CO32-) accelerates the rate of disappearance of
carboplatin in RPMI-1640 tissue culture medium, suggesting
that carbonate could be activating the drug in therapy.
In 1988 Chaney and co-workers (40) showed that bicarbonate
present in tissue culture medium could displace the malonate
chelate ring of a Pt2+ antitumor agent, suggesting that this may
be a pathway to biologically active aquo platinum complexes.
Although the products formed were analyzed by HPLC,
carbonato species were not detected in the analysis. Lack of
detection may have been due to the fact that the HPLC mobile
phase was acidic, thus accelerating the destruction of any
carbonato species formed in the reaction medium (24).
Remarkably, in nearly 40 years of physicochemical work on
the platinum drugs, with a few exceptions (40-42), carbonate
has not been present in the reaction medium. In attempting to
uncover the possible role of carbonate in the mechanism of
action of the platinum drugs, we found that a cisplatincarbonato complex forms in tissue culture medium which
contains carbonate (43), that the presence of carbonate in a
binding buffer dramatically affects the type of cisplatin lesion
which forms on DNA (44), and that Jurkat cells are able to
selectively modify a cisplatin carbonato complex by an extracellular mechanism (45). In this report we further study the
formation of carbonato complexes of carboplatin that form under
low (23.8 mM) and high (0.5 M) carbonate conditions by 13C
and 1H NMR and UV-visible spectroscopy. We also examine
the cytotoxicities of both carboplatin and mixtures of 1 and
carbonato species formed from the drug against neuroblastoma
(SK-N-SH), proximal renal tubule (HK-2), and Namalwa-luc
Burkitt’s lymphoma (BL) cells. Since carbonato complexes may
be present in therapy, we treat normal and cisplatin-resistant
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Jurkat cells with solutions containing carbonato complexes and
measure the rate at which the cells are able to take up and/or
strongly bind platinum by inductively coupled plasma mass
spectrometry (ICP-MS). The results of the study are consistent
with the hypothesis that carbonato complexes of carboplatin can
form during therapy and be the species responsible for the
antitumor effects of the drug in vivo.

Experimental Section
Materials. Carboplatin (10 mg/mL, 26.9 mM in water) was
obtained from Bedford Laboratories (Bedford, OH) and used well
before its expiration date and no later than 14 days after the initial
injection of a needle into the septum-topped formulation bottle.
Culture medium, minimum essential medium with Earle’s salts
and L-glutamine (EMEM) (10-010), RPMI-1640 (15-040), and
fetal bovine serum (FBS) were from Mediatech (Herndon, VA).
Keratinocyte-SFM (17005-042) was from Gibco Invitrogen
Corp. (Carlsbad, CA). Cell counting kit 8 (CCK-8) was purchased
from Dojindo Molecular Technologies, Inc. (Gaithersburg, MD).
Carboplatin, NaHCO3 (>99%), NaH13CO3 (98% enrichment),
and D2O (99.9%) were purchased from Sigma-Aldrich (St. Louis,
MO). HClO4 (60%) was purchased from Fisher Scientific
(Pittsburgh, PA).
13C NMR. For 13C NMR, carboplatin (5 mM) was reacted in
aqueous NaH13CO3, referred to as “aging”, in either aqueous 23.8
mM carbonate at pH 8.4 for 45 h (solution 1), 0.5 M carbonate at
pH 8.6 for 45 h (solution 2), or 0.5 M carbonate at pH 8.6 for 20
h (solution 3). After the aging period, 92 µL of D2O was added to
828 µL of each solution, solutions 1 and 2 were adjusted to pH 7.4
with HClO4, and the resulting mixtures were introduced into plasticcapped 5 mm NMR tubes. Each NMR solution was immediately
cooled to 4 °C in the probe of a Bruker Avance 500 NMR
spectrometer to slow any reactions that were occurring, and 13C
NMR data on the sample were collected. After the NMR experiment, the pH values of solutions 1 and 2 were 7.5 and 8.1,
respectively. A one-pulse sequence with proton decoupling was used
to acquire 13C NMR data. The spectral width was 220 ppm and
the total relaxation period was 10 s. The free induction decay (FID)
was Fourier-transformed by use of an exponential window function
with line-broadening parameter set at 8 Hz. A one-pulse sequence
with proton decoupling and presaturation of the bicarbonate peak
was used to acquire the carbon spectrum of solution 3. The spectral
width was 325 ppm with the offset on the bicarbonate peak at 160
ppm. The total relaxation period was 10 s with 2 s used for
presaturation. The 13CO2(aq) resonance at 125.3 ppm was used as
an internal chemical shift standard.
1H NMR. The solution for the 1H NMR spectra was prepared
by reacting 5 mM 1 in aqueous 0.5 M NaHCO3, pH 8.6, for 20 at
37 °C. After this time, an aliquot of 92 µL of D2O was added to
828 µL of the aged solution and a 1H NMR spectrum, at 37 °C,
was obtained on a Bruker Avance 600 spectrometer. The R and β
methylene protons of the cyclobutane ring of carboplatin at 2.88
ppm (triplet, 4H, 3JH-H ) 8.0 Hz) were used as an internal chemical
shift standard (9, 12).
UV-Visible Absorption Spectroscopy. UV-visible absorption
spectra were obtained on a Cary 50 spectrophotometer in a 1 cm
path length cell at room temperature. A solution containing 5 mM
carboplatin in 0.5 M NaHCO3, pH 8.6, was incubated at 37 °C. At
0, 1.5, 22, and 45 h, a 300 µL aliquot of solution was removed and
added to 2.7 mL of water, and its spectrum was recorded in the
wavelength range of 500-190 nm (60 nm/min). The final concentrations of carboplatin and carbonate buffer in the spectrophotometer
cell were 500 µM and 50 mM, respectively. A 50 mM carbonate
buffer solution was used as a baseline. Difference spectra were
obtained by subtracting the spectrum obtained immediately after
addition of 1 to the buffer (t ) 0 spectrum) from spectra taken at
1.5, 22, and 45 h. Each difference spectrum was fitted to a sum of
Gaussians by use of PeakFit (v. 4) to obtain the smoothed difference
spectrum (9).
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After ∼45 h, a small amount (<1%) of a dark insoluble material
formed in the solutions containing 5 mM 1 and 0.5 M carbonate.
This material, which could be removed by centrifugation, caused
a slight monotonic increase in absorbance toward the blue region
of the spectrum. This behavior, which is consistent with light
scattering from suspended particulate matter, suggests that at long
times a small amount of elemental platinum, Pt0, is forming in the
reaction mixture.
Neuroblastoma and Proximal Renal Tubule Cell Studies. Cell
studies were carried out under standard conditions in a humidified,
37 °C, 5% CO2 atmosphere. Human neuroblastoma (SK-N-SH) cells
in culture medium (EMEM + 10% FBS, 100 µg/mL streptomycin,
100 IU/mL penicillin, and 2.0 mM L-glutamine) and human
proximal renal tubule (HK-2) cells in serum-free culture medium
(Keratinocyte-SFM) were plated in 96-well plates, with each well
containing ∼6 × 103 cells. The viabilities of SK-N-SH and HK-2
cells, determined prior to plating by light microscopy with a
hemacytometer under standard trypan blue conditions (46), were
96% and 93%, respectively. Each experiment involved one control
plate and three identical experimental plates. After being plated,
the SK-N-SH and HK-2 cells, which were studied at different times,
were given 24 h to adhere to the bottom of the wells. A control
plate, which typically consisted of 12 wells of medium without
cells and 12 wells of medium with cells (no drug), was used to
determine the number of live cells at the beginning of an experiment
(t ) 0 was determined after the 24 h adhering time). Each
experimental plate consisted of 6 wells containing medium without
cells, 6 wells containing medium with cells, and a number of wells
containing cells to which medium containing drug at a specific
concentration/condition (g50 µM) was added. The drug conditions
for SK-N-SH cells were 1 aged in 23.8 mM or 0.5 M NaHCO3 at
37 °C, pH 8.4 or 8.6, for 0 (1), 1.5, 22, or 45 h, while the conditions
for HK-2 cells were 1 aged in 23.8 mM NaHCO3 at 37 °C, pH 8.4,
for 0 (1), 22, and 45 h.
The number of live cells in the wells of the control plate at the
beginning of a particular experiment was determined by use of the
cell counting kit, CCK-8 (Dojindo Molecular Technologies, Inc.,
Gaithersburg, MD). In this assay, 10 µL of a solution containing a
water-soluble tetrazolium salt is added to each well of the control
plate. If a specific cell is viable, the tetrazolium salt is absorbed by
the cell and bioreduced to a formazan dye, which diffuses into the
medium. After 1 h, the concentration of the formazan dye in the
well, which is proportional to the number of live cells in the well,
is determined by measuring the absorbance of the medium in the
wells at 450 nm on a luminescence plate reader (Dynex Technologies). In order to obtain the concentration (absorbance) of the dye
produced by live cells at the start of the experiment, t ) 0 h, the
absorbance at 450 nm of wells in the control plate without cells
was subtracted from the absorbance of wells in the control plate
having cells. Meanwhile, the medium above the cells in each
experimental plate was replaced with drug-containing medium at
a specific concentration/condition (6 wells per concentration/
condition per plate). After 2 h, the drug-containing medium above
the cells was removed, cells were washed with culture medium
without drug, fresh medium was applied, and the cells were allowed
to grow for 48 h. At the end of this period, the number of live
cells was determined by the method described above.
Average IC50 values, with standard deviations, were determined
by fitting individual data sets (done on different days) to exponential
curves (R2 ) 0.95 ( 0.04 and 0.86 ( 0.09 for SK-N-SH and HK-2
cell studies, respectively) and averaging experiments. The neuroblastoma cells used in this experiment had an average doubling
time of ∼30 h. The proximal tubule cells had an average doubling
time of ∼33 h. In solutions containing carboplatin aged in 0.5 M
carbonate buffer for 45 h, dark particulate material (Pt0) could be
recovered. This material was removed by centrifugation prior to
drug incubation, but control experiments showed that the material
is not toxic to cells.
Namalwa-luc Burkitt’s Lymphoma Cell Studies. The Namalwa-luc Burkitt’s lymphoma cell line, which expresses the luciferase
gene under the control of the CMV promoter, was a gift from Dr.
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Rosemary Rochford, SUNY Upstate Medical University (Syracuse,
NY). Namalwa-luc Burkitt’s lymphoma cell studies were carried
out under standard conditions in a humidified, 37 °C, 5% CO2
atmosphere. For each study, five 25 cm2 flasks were prepared, each
containing ∼4 × 105 cells/mL (94% viable) in 10 mL of culture
medium (RPMI + 10% FBS, 100 µg/mL streptomycin, 100 IU/
mL penicillin, and 2.0 mM L-glutamine). After a 2 h exposure of
the cells in four of the flasks to various concentrations (e75 µM)
of either carboplatin or carboplatin aged in 0.5 M carbonate at
37 °C, pH 8.6, for 0 (1) or 22 h, the cells in all five flasks were
washed twice by sedimenting the cells for 5 min at 450g, removing
the medium, and resuspending the cells in 10 mL of fresh medium.
After two washes and a 1:1 dilution with culture medium, 3 mL of
each of the five conditions were placed into culture tubes with each
tube containing ∼1.6 × 105 viable cells/mL. Cells were then
allowed to grow for 48 h, after which time the number of viable
cells in each culture tube was measured by use of trypan blue (46).
Average IC50 values were determined by fitting each data set to an
exponential curve (R2 ) 0.86 ( 0.09). The BL cells used in this
experiment had an average doubling time of ∼57 h.
Platinum Uptake by Jurkat Cells and Cisplatin-Resistant
Jurkat Cells. Six samples, each containing 3.5 × 106 cells
suspended in 896 µL of culture medium (RPMI + 10% FBS, 100
µg/mL streptomycin, 100 IU/mL penicillin, and 2.0 mM Lglutamine), were used in each uptake study, and both normal Jurkat
(NJ) and cisplatin-resistant Jurkat (RJ) cell lines were studied. The
RJ cell line was a gift from Mr. Corey Centerwall, Syracuse
University (Syracuse, NY). The NJ and RJ cells were ∼92% and
∼98% viable, respectively, at the beginning of each experiment.
Viabilities were determined by light microscopy with a hemacytometer and trypan blue. After 5 h in a sealed tube, the viabilities
of NJ and RJ cells were ∼64% and ∼90% viable, respectively. To
each sample, 24 µL of either 5 mM 1 or 5 mM 1 aged in 23.8 mM
NaHCO3 pH 8.4, for 45 h at 37 °C was added, giving a final
platinum concentration of 130 µM. Five samples of each condition
were placed in capped Eppendorf tubes and placed in a 37 °C
incubator, while the cells in one tube were immediately pelleted
by centrifugation for 3 min at 200g. After centrifugation, culture
medium was removed and cells were resuspended in 1 mL of
phosphate-buffered saline (PBS). The cells were pelleted a second
time by centrifugation, the PBS was removed, and the cells were
digested for 48 h at 70 °C in 0.5 mL of 70% (v/v) nitric acid/
water. This procedure was repeated every hour for a total of 5 h
on the cells exposed to drug. The nitric acid solutions of digested
cells were analyzed for platinum by ICP-MS (Department of
Engineering, Syracuse University). The uptake rate per cell, in
attomoles of Pt per hour per cell, was calculated from the total
number of viable cells at t ) 0 (3.5 × 106) and the number of
moles of platinum that each cell removed from the culture medium
per hour.

Results
As was earlier shown by us (9), the attacking nucleophile
for the ring-opening reaction of carboplatin to give carbonatocarboplatin, 2, is carbonate ion (Scheme 1). Once formed, 2
could produce a number of possible products, four of which
are shown in Scheme 1. Because the species in the scheme are
in equilibrium with each other through the addition or loss of
CO2 and the carbonato species can be protonated to their
respective bicarbonato forms, which could either remain in
solution or rapidly dicarboxylate to Pt aquo/hydroxo compounds,
isolation of pure carbonato compounds was exceedingly difficult. After repeated unsuccessful attempts to isolate materials,
we decided to generate carbonate species in solution by the
reaction of 1 in carbonate buffer and determine the species
present in the aged medium by use of spectroscopy. These
solutions were then used to treat cells and study platinum uptake.
13C NMR. 13C NMR spectra of carboplatin that has been
aged in carbonate buffer under various conditions are shown in

Figure 1. (a) 13C NMR spectrum of a solution containing 5 mM
carboplatin aged in 23.8 mM NaH13CO3, pH 8.4, for 45 h at 37 °C.
The spectrum shown was obtained after 10% D2O was added and the
pH was adjusted to 7.4, at 4 °C. The final solution contained 4.5 mM
1 in 21.4 mM NaH13CO3. (b) 13C NMR spectrum of a solution
containing 5 mM carboplatin aged in 0.5 M NaH13CO3, pH 8.6, for 45
h at 37 °C. The spectrum shown was obtained after 10% D2O was
added and the pH was adjusted to 7.4, at 4 °C. The final solution
contained 4.5 mM 1 in 0.45 M NaH13CO3. (c) 13C NMR spectrum of
a solution containing 5 mM carboplatin aged in 0.5 M NaH13CO3, pH
8.6, for 20 h at 37 °C. The spectrum shown was obtained after the
addition of 10% D2O at 4 °C. The final solution contained 4.5 mM 1
in 0.45 M NaH13CO3.

Figure 1. Although aging, that is, letting 1 react in carbonate
medium, was carried out at 37 °C, the actual 13C NMR spectral
data were collected at 4 °C. The lower temperature slowed the
reaction kinetics, which helped improve the quality of spectra
during the lengthy (20-40 h) NMR data collection period.
Aging carboplatin (5 mM) in 23.8 mM NaH13CO3 at pH 8.4 or
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in 0.5 M NaH13CO3 at pH 8.6, for 45 h at 37 °C, followed by
adjusting the pH of the solution to 7.4 and collecting NMR data
at low temperature, gave the spectra shown in Figure 1a,b.
Figure 1a shows two strong peaks at 161.2 and 125.3 ppm that
are due to HCO3-/CO32- and CO2(aq), respectively (24, 43,
47-49). Since the transfer of the proton between HCO3- and
CO32- is fast on the NMR time scale, bicarbonate and carbonate
together give a single signal, the chemical shift of which depends
on pH. Although gaseous CO2 reacts with water to give carbonic
acid, H2CO3, which enters into equilibrium with HCO3-/CO32-,
the kinetics of hydration of carbon dioxide is slow on the NMR
time scale (24), which is the reason dissolved CO2 appears as
a distinct resonance at 125.3 ppm. By comparison with 13C
NMR spectra of carbonato complexes of Zn2+ (47-49) and Pt2+
(31, 43), the signals at 169.2 and 166.9 ppm are assigned to
platinum carbonato complexes that form in the reaction of 1
with NaH13CO3. Earlier work by us on the reaction of cisplatin
in carbonate medium (43) produced a product having a 13C
NMR resonance at 167.0 ppm that was assigned to cis-[Pt(NH3)2(CO3)2]2- (3, Scheme 1). Since the reaction of 1 in
carbonate yields a complex with a similar chemical shift, 166.9
ppm in Figure 1a, this species is likely also 3. As is evident
from the low intensity of the platinum carbonato resonances,
not much of 1 has reacted with carbonate. Since the reaction is
in its early stages and since the higher-field signal, at 166.9
ppm, is associated with a compound that forms in the cisplatin
system (i.e., 3), the resonance at 169.2 ppm is likely 2, carbonato
carboplatin.
Aging 1 in 0.5 M NaH13CO3 produces additional amounts
of platinum-carbonato complexes (Figure 1b). These appear
as strong resonances at 169.1 ppm (2) and 167.3 ppm (3),
although, as will be evident below, the latter may be overlapped
with the resonance of another species. From the weaker signals
observed in Figure 1b, which are associated with naturalabundance 13C in the CBDCA ligand, it is clear that both intact
1 and free CBDCA are present in solution. The resonances for
the R and β carbons of the cyclobutane ring of 1 occur at 31.7
ppm, while the resonances for the same carbons in the free
ligand, CBDCA, are observed at 30.9 ppm (50).
Figure 1c is the 13C NMR spectrum of the reaction mixture
after 1 is aged in 0.5 M NaH13CO3, pH 8.6, for 45 h at 37 °C
and NMR data are obtained at 4 °C. The spectrum shows 2 at
168.8 ppm and two resonances at 168.0 and 167.9 ppm, as well
as free CBDCA (R and β carbons) at 30.8 ppm. Since panels b
and c refer to solutions differing in pH (7.4 for Figure 1b vs
8.6 for Figure 1c), the higher-field resonance appears to be an
overlap of two platinum-carbonato species, one of which is
likely 3.
1H NMR. The 1H NMR spectrum of 5 mM 1 in 0.5 M
carbonate buffer for 20 h at 37 °C is shown in Figure 2. The
triplet (3JH-H ) 8.0 Hz) at 2.88 ppm is associated with the
symmetry-equivalent methylene protons on the R and β positions
of the cyclobutane ring of 1, while the quintet (3JH-H ) 8.0
Hz) at 1.90 ppm is associated with the two methylene protons
on the γ position of the four-membered ring (Scheme 1). The
triplet in Figure 2 centered at 2.34 ppm (3JH-H ) 8.0 Hz) is
due to the R and β protons of the CBDCA ligand of the ringopened compound, carbonato-carboplatin, 2, which is monodentate to Pt2+ (Scheme 1). This assignment parallels that for
the equivalent ring-opened compounds in which the CO32ligand of 2 has been replaced with HPO42- (12). The quintet at
1.82 ppm is due to the two methylene protons on the γ position
of the cyclobutane ring of 2. When aged in carbonate buffer
for 20 h, 2 further reacts with carbonate, releasing the free
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Figure 2. 1H NMR spectrum of a solution containing 5 mM carboplatin
aged in 0.5 M NaHCO3, pH 8.6, for 20 h at 37 °C. The spectrum shown
was obtained after the addition of 10% D2O. The final solution
contained 4.5 mM 1 in 0.45 M NaHCO3.

Figure 3. UV difference spectra of 1 in 0.5 M carbonate buffer, pH
8.6, at 1.5 h (lowest curve on left), 22 h (middle curve on left), and 45
h (highest curve on left).

CBDCA ligand to solution (Scheme 1). At the pH of the study,
all of the methylene proton resonances of free CBDCA2overlap with the corresponding resonances of 2 (12). From
integration of the resonances in the spectrum, the composition
of the solution at 20 h is 69% 1 and 31% ring-opened species.
Using this information, we calculate a pseudo-first-order decay
constant of k1 ≈ 4.31 × 10-6 s-1 for the disappearance of 1 in
0.5 M carbonate buffer at 37 °C, pH 8.6, which is approximately
1.3 times as large as the rate constant for the disappearance of
1 in 23.8 mM carbonate under the same conditions.
UV-Visible Absorption Spectra. UV-visible absorption
spectroscopy is useful for following the reaction of 1 in
carbonate buffer. In analyzing the time course of the reaction,
it is convenient to obtain difference spectra by subtraction of
the spectrum obtained at “zero time” from spectra taken at later
times. This gives the results shown in Figure 3. At t ) 1.5 h,
a difference spectrum characteristic of a solution containing both
1 and 2 was obtained (9). The difference spectra at t ) 22 and
45 h show that the positive absorption at 200-210 nm, which
is attributed to the formation of 2, and the negative absorption
at 230-240 nm, which is attributed to the depletion of 1, become
more pronounced with time, as does the positive absorption at
∼270 nm (9). At later times, a positive absorption at ∼350 nm,
which also grows with time, is clearly visible. The positive
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Table 1. Uptake Rates of Carboplatin and Solutions of Carboplatin
plus Its Carbonate Reaction Products by Normal and Resistant
Jurkat Cells
conditiona
1
aged 1
1
aged 1

cell lineb
NJ
NJ
RJ
RJ

rate of uptakec (amol of Pt h-1 cell-1)
16.6 ( 4.2
14.5 ( 4.1
12.3 ( 4.8
5.1 ( 3.3

a Either 130 µM 1 or 130 µM 1 aged in 23.8 mM NaHCO at 37 °C for
3
45 h. b NJ, normal Jurkat cells; RJ, Jurkat cells that have been made resistant
c
-18
to cisplatin. Attomole (amol) ) 10
mol.

Figure 4. Calculated IC50 values (micromolar), with statistical errors,
where blue is 1 aged in 23.8 mM carbonate toward SK-N-SH, yellow
is 1 aged in 0.5 M carbonate toward SK-N-SH, red is 1 aged in 23.8
mM carbonate toward HK-2, and green is 1 aged in 0.5 M carbonate
toward BL. See Experimental Section for further details.

produced by aging is greatest for HK-2 cells; that is, these cells
are most affected by the presence of the carbonate reaction
products. Interestingly, for SK-N-SH cells, aging for the same
period of time in 23.8 mM or 0.5 M NaHCO3 produces about
the same IC50 value.
Platinum Uptake by Normal and Cisplatin-Resistant
Jurkat Cells. Figure 5 shows cellular Pt concentrations
(determined by ICP-MS) as functions of time, with least-squares
linear fits. As is evident from Table 1, the rates of platinum
uptake by normal Jurkat (NJ) cells are the same for fresh
carboplatin solutions and solutions aged in carbonate, that is,
∼15 amol of Pt h-1 cell-1. However, for Jurkat cells that were
made resistant to cisplatin by continued exposure to the drug,
uptake of platinum from solutions that contain carbonate reaction
products was much less than uptake from solutions containing
1 alone. This is consistent with RJ cells being more efficient
than NJ cells in eliminating and/or preventing binding of
platinum complexes that are “cisplatin-like” (carbonate reaction
products) in nature.

Discussion
13C

Figure 5. Platinum (in attomoles, 10-18 mol) taken up per normal
Jurkat (NJ) or cisplatin-resistant Jurkat (RJ) cell, when exposed to
carboplatin alone or aged carboplatin, as a function of time. Total
concentration of platinum in the culture medium for each condition,
130 µM; aging conditions, 5 mM carboplatin, 23.8 mM NaHCO3 for
45 h, pH 8.4, 37 °C. ([, black line) Carboplatin alone + NJ cells; (9,
dashed line) aged carboplatin + NJ cells; (2, dark gray line) carboplatin
+ RJ cells; (b, light gray line) aged carboplatin + RJ cells. See
Experimental Section for further details.

absorption at ∼350 nm, which is probably of d-d origin, is
shifted to lower energy than the corresponding absorption for
1 (9). This is consistent with a decrease in the magnitude of
the crystal field when the bidentate dicarboxylate CBDCA
chelate ring is opened and one or more of the coordination sites
on Pt2+ is replaced by carbonate (14, 51, 52).
Cytotoxicity Studies. Carboplatin and aged solutions of 1
in carbonate were used to treat human neuroblastoma (SK-NSH), human proximal renal tubule (HK-2), and human Namalwa-luc Burkitt’s lymphoma (BL) cells in culture. As is evident
from Figure 4, the order of the IC50 values for the three cell
lines studied is BL < SK-N-SH < HK-2, which shows that
carboplatin is most toxic to BL cells but least toxic to HK-2
cells. Since carboplatin is known to have low nephrotoxicity,
this behavior is expected (1). Also evident from Figure 4 is
that increases in the aging time of 1 in carbonate medium cause
decreases in the measured IC50 value for all three cell lines.
This shows that the products produced by aging in carbonate
are more toxic to cells than is carboplatin itself. Also evident
from Figure 4 is that the fractional decrease in the IC50 value

The
NMR spectra (Figure 1) clearly show that carbonato
complexes are formed in the reaction of carboplatin in carbonate
buffer. However, as is evident from Scheme 1, the system is
complicated and even at early stages of the reaction more than
one platinum-carbonato species is present in solution. Since
the 13C NMR chemical shift of the high-field resonance in Figure
1 (a, b) in carbonate buffer is nearly identical to the resonance
of the carbonato species observed in the cisplatin system (43),
it is assigned to cis-[Pt(NH3)2(CO32-)2] (3, Scheme 1). This
implies that free CBDCA is present, which is confirmed by the
natural-abundance 13C NMR resonances for the ligand observed
in Figure 1b. However, since aqueous CO2 is in a hydrogenion-dependent equilibrium with all carbonato compounds, other
species, some of which are shown in Scheme 1, are possible.
The complexity of the system is evident in Figure 1c, which
shows that an increase in pH causes the high-field signal to
move to lower field and split into two resonances. The complex
nature of aqueous solutions containing carbonato complexes has
been recognized by van Eldik and co-workers (47-49), who
reported that zinc-carbonato complexes that should give simple
13C NMR patterns often yielded spectra having multiple
resonances, indicating the presence of a number of species.
While 1H NMR has high sensitivity, thus allowing short NMR
data collection times, the proton resonances of free CBDCA
and CBDCA monodentate to platinum, as in 2, are overlapped
at near-neutral values of pH (Figure 2). Sadler and co-workers
(12) showed that it is possible to observe the difference between
free and monodentate CBDCA by making the solution acidic.
The fact that carbonato complexes would not survive at high
hydrogen ion concentration precluded this approach as a means
of distinguishing between free and monodentate CBDCA in
carbonate medium. However, since resonances for 1 are not
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overlapped with others in the spectrum (Figure 3), the kinetics
of the reaction of 1 with carbonate can be measured easily from
the 1H NMR signal integrations as a function of time. As earlier
stated, this yielded a pseudo-first-order rate constant k1 ≈ 4.31
× 10-6 s-1 for the disappearance of 1 in 0.5 M carbonate buffer
at 37 °C, pH 8.6. This rate constant is only 1.3 times as large
as the rate constant for the disappearance of 1 in 23.8 mM
carbonate under the same conditions. Note, however, that the
Debye-Huckel theory gives the following expression for γC
(activity coefficient of CO32-):

ln (γC) )

-z2AxI
1 + BaxI

Here, z is ionic charge (-2), I is the ionic strength (≈molarity
for NaHCO3 solution), A ) 1.17(mol/kg)-1/2, B ) 3.3 × 109
(mol/kg)-1/2 m-1, and a is an ionic diameter. Assuming a ) 5
× 10-10 m, this formula gives γC ) 0.562 for 23.8 mM and
0.217 for 0.5 M, so that aC, the activity of CO32-, at 0.5 M is
only ∼8 times aC at 0.0238 M. Ion pairing and association
effects, very important at high concentration, will reduce the
ratio even further. The low ratio of rate constants in 0.5 and
0.0238 M bicarbonate is thus not entirely unexpected.
In addition to NMR, UV-visible difference spectroscopy is
also useful for following the reaction of 1 in carbonate medium
(Figure 3). Although this approach is quite sensitive to changes
in the composition of the solution, it so far provides a largely
qualitative assessment of the progress of the reaction. To be
more quantitative, additional information on the molar extinction
coefficients of the species present is required.
As earlier stated, the hypothesis that formed the basis for
this study is that carboplatin is activated by carbonate and that
carbonato species are responsible for the antitumor effects
(cytotoxicity) of the drug in therapy. This hypothesis, which
requires that the products of activation, carbonato complexes,
be more lethal to cells than carboplatin alone, is supported by
the data shown in Figure 4. Clearly, aging carboplatin in
carbonate medium produces species that are more toxic to all
cell lines studied than carboplatin alone. Moreover, increasing
the aging time, which results in the formation of additional
carbonato species, increases the toxicity of the platinum forms
in solution that attack the cells. Human renal proximal tubule
cells (HK-2) experience the greatest loss in survival upon
exposure to the carbonato species formed after carboplatin is
aged in carbonate at 37 °C for 22 h, as compared to carboplatin
alone. However, as is evident from Figure 4, of the three cell
lines studied, HK-2 cells have the highest values of IC50, so
that they remain the most resistant to the toxic effects of the
carbonato forms in the culture medium. Since carboplatin is
known to exhibit relatively low renal toxicity (1, 53), the
observed low toxicity of the carbonato forms toward HK-2 cells
is consistent with the hypothesis that carbonato species could
form in therapy and be the species responsible for the antitumor
effects of the drug. The carbonato species could be circulating
in the body, attacking other types of cells, but not be especially
damaging to kidney cells. While spectroscopy shows that
increasing the concentration of carbonate in the aging buffer
containing carboplatin results in the formation of more ringopened product in a given period of time, Figure 4 shows that
low (23.8 mM) and high (0.5 M) carbonate-platinum solutions
have almost the same IC50 values for human neuroblastoma SKN-SH cells. Although more carbonato species are formed at
higher concentration, neither the concentrations nor the cytotoxicities of the species are known. Thus solutions aged under
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different conditions could in fact lead to the same cytotoxicities,
as is apparently the case.
As is shown in Figure 5 and Table 1, normal Jurkat cells
(NJ) and Jurkat cells that have been made resistant to cisplatin
(RJ) both take up platinum. The uptake rates are about the same
for both cell lines when exposed to carboplatin alone, but when
exposed to carboplatin that has been aged in carbonate medium,
normal Jurkat cells take up Pt more than twice as fast as resistant
cells. Since carboplatin alone has only a small amount of
carbonato species (see the statements on hydrolysis above) and
aged carboplatin has a lot more, this suggests that resistant cells
can act on the carbonato species to prevent it from entering
cells.
Note that each cell takes up a very small fraction of the total
platinum from the solution that is above it. For example, in
these experiments each reaction tube contained 0.12 µmol of
Pt in 920 µL of solution. As we show in this work, when
exposed to carboplatin, a single normal Jurkat cell takes up 16.6
amol of Pt in 1 h, which represents 1.4 × 10-10 of the total
amount of Pt present in the solution above the cells. In previous
work, we showed that Jurkat cells exposed to 65 µM cisplatin
in the presence of carbonate-containing culture medium took
up Pt at a rate of 125 amol of Pt h-1 cell-1 (45). Thus, of the
0.060 µmol of Pt present in 920 µL of the cisplatin solution
used, the fraction that was taken up by a single cell is 2.1 ×
10-9, showing that the ratio of uptake rates for cisplatin and
carboplatin is (21 × 10-10)/(1.4 × 10-10) ) 15. This is close
to the 13.3 ratio seen with the L1210 murine lymphomasrcoma
cell line for the two drugs (54). Ghezzi et al. (55) found the
ratio of uptake rates, cisplatin to carboplatin, to be 3.1 for
MCF-7 breast cancer cells. Pereira-Maia and Garnier-Suillerot
(56) found ratios of 15 and 8 for susceptible and resistant small
lung-cancer cells. They reported Pt uptake rates of ∼0.2 mM
h-1 for lung-cancer cells exposed to 100 µM cisplatin (average
over four cell types); with an assumed cell volume of 10-12 L,
this corresponds to 200 amol of Pt h-1 cell-1, about the same
as we found for Jurkat cells. Other values of uptake rates and
a discussion of the mechanisms by which the platinum drugs
enter the cell have been previously published (7, 57).
With a binding rate of ∼15 amol of Pt h-1 cell-1, about 9
million platinum ions in some chemical form strongly bind to
the cell in 1 h. Earlier studies by us (58) and by Ghezzi et al.
(55) show that only about 1% of the ions that bind to the cell
are actually bound to DNA, so that ∼90 000 Pt ions would be
attached to genomic DNA in 1 h. Since cells exposed to
conditions similar to those used here would enter into druginduced apoptosis (58), reaction of the remaining 99% of the
Pt bound to the cell with molecules other than DNA
could be responsible for the initiation of death. As pointed out
by Bose (6), there are many potential non-DNA targets, the
platination of which could jeopardize the survival of the cell.
Clearly, additional study to resolve this important issue appears
warranted.
As is evident from Figure 5 and Table 1, RJ cells have
reduced capacity to bind platinum when in contact with solutions
containing significant concentrations of carbonato species. This
is probably because the RJ cells were selected for their ability
to survive higher concentrations of cisplatin and their survival
is associated with mechanisms to prevent platinum from entering
cells, by chemically modifying it in solution (45), and/or rapidly
removing platinum from cells by an efflux mechanism. Since
substitution reactions occur at much greater rates with cisplatin
than with carboplatin, the products shown on the right side of
Scheme 1 would be present in significant concentrations in the
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solutions to which cells are exposed when selecting cells for
their resistance to cisplatin. Thus it is not surprising that the RJ
cells exhibit reduced uptake (reduced amount of platinum
strongly bound to the cell) from solutions containing these
species. This implies that carbonato species, regardless of the
drug from which they are derived (i.e., cisplatin or carboplatin),
are highly toxic to the cells and cell survival depends on finding
mechanisms to minimize exposure to these agents.
During intravenous infusion of carboplatin, the concentration
of the drug in blood is ∼130 µM (53). While it is widely
believed that the drug is entirely in the chelated form 1 (Scheme
1), this is clearly not the case: infusion solutions contain small
amounts (a few percent) of the hydrolyzed form (39). The pKa
values for deprotonation of the cisplatin aquo complexes are
near physiological pH (13), and it is likely that a carboplatin
aquo species would have a pKa for deprotonation in the same
range. Since hydroxo compounds can react rapidly with aquated
CO2 to form carbonato complexes, injection of the infusion
solution of carboplatin into blood could lead to the rapid
formation of small amounts of 2 and other species shown in
Scheme 1. As we earlier showed (9), carbonate ion CO32-, small
concentrations of which are present in blood, can displace the
CBDCA chelate ring of 1, and the ion appears to be an important
nucleophile for attacking carboplatin in the aggressive nucleophilic environment of culture medium (9, 43). Our findings show
that carbonato species are significantly more toxic to neuroblastoma, proximal tubule, and BL cells than 1, so even small
concentrations of these species in therapy may be important.
Although carbonato complexes have not been detected in
therapy, free CBDCA has been found in the urine of cancer
patients who have received carboplatin (17), indicating that some
nucleophile present in the body, perhaps but not necessarily
carbonate, can completely displace the chelate ring of carboplatin.
As is shown in Scheme 1, the reaction of carboplatin in
carbonate medium produces a number of complexes that are
anions which, as the cytotoxicity studies show, are toxic to the
cell. While the mechanism used by these compounds for entering
the cell is unknown, anionic drugs, toxins, and xenobiotics
having molecular weights similar to those shown in Scheme 1
enter the cell by use of organic anion-transporting polypeptides
(OAT) (59). This transporter, which has many variations, can
be found in multiple tissues including the blood-brain barrier,
kidney, heart, lung, placenta, and testis. For example the
anticancer drug methotrexate, which is a dianion and has a
molecular mass of ∼450 Da, is believed to be taken into mouse
proximal tubule cells by an OAT (60). These transporters have
also been implicated in resistance in that they appear to facilitate
the removal of drugs from the cell (61). Recently, Zhang et al.
(62) studied the uptake of cisplatin, carboplatin, and oxaliplatin
by cells having overexpressed organic cation transporters, OCT.
The study concluded that oxaliplatin, but not cisplatin or
carboplatin, is an excellent substrate for OCT, suggesting that
a cationic forms of this platinum drug may be present in the
medium and taken up by the cell.
In summary, entry of a carbonate ligand into the primary
coordination sphere of a platinum anticancer drug creates a
variety of different reaction and transport options for the drug
under biological conditions. As this study shows, carbonato
complexes of carboplatin are capable of killing cells, which
indicates that they are taken up by the cell and can interact with
critical cellular components to induce apoptosis. Clearly,
additional work will be needed to further characterize the
structures of these interesting compounds, the factors that control
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their rates and mechanism of formation, and most importantly,
the molecular mechanism by which they kill cells.
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